Furthermore, NCT03091491 is a phase II study in Asia evaluating Nivolumab versus the combination of Nivolumab and Ipilimumab in a patient with EGFR mutation NSCLC who has failed first-line TKI therapy [106,107]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.